Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 90565
1. van Middelaar T, van Vught LA, van Charante EPM, Eurelings LSM, Ligthart SA, van Dalen JW, van den Born BJH, Richard E, van Gool WA: Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens; 2017 Oct;35(10):2095-2101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower dementia risk with different classes of antihypertensive medication in older patients.
  • OBJECTIVE: Use of antihypertensive medication (AHM) is potentially associated with a reduced risk of dementia.
  • We aimed to study the association between different classes of AHM and dementia in older people.
  • METHODS: A subgroup of community-dwelling older people using AHM included in the 'Prevention of Dementia by Intensive Vascular Care' randomized controlled trial was studied.
  • Incident dementia rates in participants with different AHM classes (mono and combination therapy) were compared with dementia rates in participants with any other AHM.
  • After 6.7 years (interquartile range 6.0-7.3) of follow-up, 136 participants (7.0%) developed dementia.
  • Both use of CCBs [hazard ratio 0.56, 95% confidence interval (95% CI) 0.36-0.87] and ARBs (hazard ratio 0.60, 95% CI 0.37-0.98) were independently associated with a decreased risk of dementia.
  • The association of CCBs with dementia was most apparent in participants without a history of cardiovascular disease (hazard ratio 0.38, 95% CI 0.18-0.81) and with uncontrolled hypertension (hazard ratio 0.26, 95% CI 0.11-0.61).
  • CONCLUSION: Both use of CCBs and ARBs are independently associated with a decreased risk of dementia in older people.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28509727.001).
  • [ISSN] 1473-5598
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. von Gunten A, Schlaefke S, Überla K: Efficacy of Ginkgo biloba extract EGb 761<sup>®</sup> in dementia with behavioural and psychological symptoms: A systematic review. World J Biol Psychiatry; 2016 Dec;17(8):622-633
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of Ginkgo biloba extract EGb 761<sup>®</sup> in dementia with behavioural and psychological symptoms: A systematic review.
  • OBJECTIVES: To review current evidence of efficacy of Ginkgo biloba extract EGb 761<sup>®</sup> in dementia with behavioural and psychological symptoms (BPSD).
  • METHODS: Randomized, placebo-controlled trials assessing the effects of EGb 761<sup>®</sup> in dementia patients with BPSD were included if the diagnosis was made in accordance with internationally accepted criteria, the treatment period was at least 22 weeks, outcome measures covered BPSD and at least two of the following domains of assessment, i.e. cognition, activities of daily living and clinical global assessment, and methodological quality was adequate.
  • RESULTS: Four published trials were identified, involving altogether 1,628 outpatients with mild to moderate dementia.
  • CONCLUSIONS: The pooled analyses provide evidence of efficacy of EGb 761<sup>®</sup> at a daily dose of 240 mg in the treatment of out-patients suffering from Alzheimer's, vascular or mixed dementia with BPSD.
  • [MeSH-major] Alzheimer Disease / drug therapy. Dementia / drug therapy. Plant Extracts / administration & dosage

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26223956.001).
  • [ISSN] 1814-1412
  • [Journal-full-title] The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • [ISO-abbreviation] World J. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plant Extracts; 19FUJ2C58T / Ginkgo biloba extract
  • [Keywords] NOTNLM ; Alzheimer's disease / EGb 761® / Ginkgo biloba / dementia / vascular dementia
  •  go-up   go-down


3. [Therapy of brain function disorders in the elderly. Proven therapeutic results with Ginkgo-biloba extract in degenerative and vascular dementia. Report of a symposium. Munich, 7 December 1990]. Fortschr Med Suppl; 1991;107:1-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of brain function disorders in the elderly. Proven therapeutic results with Ginkgo-biloba extract in degenerative and vascular dementia. Report of a symposium. Munich, 7 December 1990].
  • [MeSH-major] Dementia / drug therapy. Dementia, Vascular / drug therapy. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1672525.001).
  • [ISSN] 0932-5611
  • [Journal-full-title] Fortschritte der Medizin. Supplement : die Kongressinformation für die Praxis
  • [ISO-abbreviation] Fortschr Med Suppl
  • [Language] ger
  • [Publication-type] Congresses; Overall
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Ginkgo biloba extract 761; 0 / Plant Extracts
  •  go-up   go-down


Advertisement
4. Cherbuin N: Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia. Evid Based Ment Health; 2013 Feb;16(1):26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher dietary intakes of potassium, calcium and magnesium are associated with a reduced risk of developing vascular dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Am Geriatr Soc. 2012 Aug;60(8):1515-20 [22860881.001]
  • (PMID = 23154787.001).
  • [ISSN] 1468-960X
  • [Journal-full-title] Evidence-based mental health
  • [ISO-abbreviation] Evid Based Ment Health
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Maurer K, Ihl R, Dierks T, Frölich L: Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Phytomedicine; 1998 Dec;5(6):417-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type.
  • Among the psychiatric illnesses associated with old age primary degenerative dementia of the Alzheimer type (DAT) has gained increasing importance in recent years.
  • Even though a curative treatment of the disease is currently impossible, various drugs can be used to slow down its progression.
  • The primary outcome variable was the sum score in the SKT-test for the determination of attention and memory.
  • In addition to this psychometric confirmation of efficacy, certain descriptive trends were found at the psychopathological (Clinical Global Impression) and dynamic functional (EEG findings) levels, which can be interpreted as evidence of effectiveness of Ginkgo biloba special extract EGb 761 in mild to moderate dementia and of local effects in the central nervous system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 1998 Gustav Fischer Verlag. Published by Elsevier GmbH.. All rights reserved.
  • (PMID = 23196024.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Cacabelos R: [Tacrine: first generation of anti-dementia drugs]. Med Clin (Barc); 1995 Jun 17;105(3):105-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tacrine: first generation of anti-dementia drugs].
  • [MeSH-major] Dementia / drug therapy. Tacrine / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 7603108.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] SPAIN
  • [Chemical-registry-number] 4VX7YNB537 / Tacrine
  • [Number-of-references] 148
  •  go-up   go-down


7. Ancelin ML, Carrière I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy AM, Ritchie K: Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis; 2012;30(3):629-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid lowering agents, cognitive decline, and dementia: the three-city study.
  • Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, 4, and 7 year follow-up.
  • For women but not men, fibrate use was specifically associated with an increased risk over 7 years of decline in visual memory only (HR = 1.29, 95% CI = 1.09-1.54, p = 0.004), and did not increase risk for incident dementia.
  • For both genders, no significant associations were found between statins (irrespective of their lipophilicity) and either cognitive decline or dementia incidence.
  • This prospective study, adjusting for multiple confounders, found no evidence that LLA given in late life reduced the risk of cognitive decline and dementia, but did raise the possibility that women with treatment-resistant high LDL-cholesterol may be at increased risk of decline in visual memory.
  • [MeSH-major] Cognition / drug effects. Cognition Disorders / epidemiology. Dementia / epidemiology. Fibric Acids / pharmacology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Statins.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Nov 11;356(9242):1627-31 [11089820.001]
  • [Cites] Eur J Pharmacol. 2012 Jan 5;674(1):33-43 [22056833.001]
  • [Cites] Lancet. 2002 Jul 6;360(9326):7-22 [12114036.001]
  • [Cites] Lancet. 2002 Nov 23;360(9346):1623-30 [12457784.001]
  • [Cites] Circulation. 2002 Dec 17;106(25):3143-421 [12485966.001]
  • [Cites] Neuroepidemiology. 2003 Nov-Dec;22(6):316-25 [14598854.001]
  • [Cites] Womens Health Issues. 1992 Summer;2(2):102-11; discussion 111-3 [1617306.001]
  • [Cites] Stat Med. 1998 Sep 15;17(17):1973-88 [9777690.001]
  • [Cites] Arch Gen Psychiatry. 2005 Feb;62(2):217-24 [15699299.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1583-7 [15947175.001]
  • [Cites] Arch Neurol. 2005 Jul;62(7):1047-51 [16009757.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1802-10 [16522699.001]
  • [Cites] Neurology. 2007 Nov 6;69(19):1873-80 [17984456.001]
  • [Cites] Climacteric. 2008 Feb;11(1):74-83 [18202967.001]
  • [Cites] Am J Geriatr Psychiatry. 2008 May;16(5):343-54 [18448847.001]
  • [Cites] Neurology. 2008 May 6;70(19 Pt 2):1795-802 [18199831.001]
  • [Cites] Neurology. 2008 Jul 29;71(5):344-50 [18663180.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):979-84 [18450788.001]
  • [Cites] Psychol Aging. 2008 Sep;23(3):608-20 [18808250.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7 [18931004.001]
  • [Cites] Psychoneuroendocrinology. 2009 Feb;34(2):287-98 [18947934.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):11-7 [19266697.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD003160 [19370582.001]
  • [Cites] Arch Intern Med. 2009 Jul 27;169(14):1317-24 [19636034.001]
  • [Cites] Vascul Pharmacol. 2009 Nov-Dec;51(5-6):323-30 [19732852.001]
  • [Cites] J Neurol. 2010 Jan;257(1):85-90 [19653027.001]
  • [Cites] JAMA. 2010 Jan 13;303(2):150-8 [20068209.001]
  • [Cites] Neurology. 2010 Mar 23;74(12):956-64 [20200346.001]
  • [Cites] J Am Geriatr Soc. 2010 Jul;58(7):1311-7 [20533968.001]
  • [Cites] Neurology. 2011 Aug 9;77(6):556-63 [21795660.001]
  • [Cites] Arch Neurol. 2011 Oct;68(10):1239-44 [21987540.001]
  • [Cites] Arch Neurol. 2011 Nov;68(11):1385-92 [22084122.001]
  • [Cites] Arch Neurol. 2002 Feb;59(2):223-7 [11843693.001]
  • (PMID = 22451317.001).
  • [ISSN] 1875-8908
  • [Journal-full-title] Journal of Alzheimer's disease : JAD
  • [ISO-abbreviation] J. Alzheimers Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Fibric Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Other-IDs] NLM/ HALMS707350; NLM/ PMC3743740
  •  go-up   go-down


8. Gulmann NC, Kristensen MO: [Anticholinergic delirium in patients with dementia. Senile dementia - a contraindication for treatment with anticholinergic agents]. Ugeskr Laeger; 1984 Jan 16;146(3):194-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anticholinergic delirium in patients with dementia. Senile dementia - a contraindication for treatment with anticholinergic agents].
  • [Transliterated title] Antikolinergt delir hos demente patienter. Senil demens - en kontraindikation for behandling med antikolinergika.
  • [MeSH-major] Delirium / etiology. Dementia / complications. Parasympatholytics / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Psychoses, Substance-Induced / etiology

  • MedlinePlus Health Information. consumer health - Delirium.
  • MedlinePlus Health Information. consumer health - Dementia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 6701981.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Parasympatholytics
  •  go-up   go-down


9. Smeets CHW, Gerritsen DL, Zuidema SU, Teerenstra S, van der Spek K, Smalbrugge M, Koopmans RTCM: Psychotropic drug prescription for nursing home residents with dementia: prevalence and associations with non-resident-related factors. Aging Ment Health; 2017 Jul 20;:1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychotropic drug prescription for nursing home residents with dementia: prevalence and associations with non-resident-related factors.
  • OBJECTIVES: To determine psychotropic drug prescription rates in nursing home residents with dementia and to identify associations with the so far understudied psychosocial non-resident-related factors.
  • METHOD: A cross-sectional, observational, exploratory design as part of PROPER I (PRescription Optimization of Psychotropic drugs in Elderly nuRsing home patients with dementia).
  • Participants were 559 nursing home residents with dementia, 25 physicians, and 112 nurses in the Netherlands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28726490.001).
  • [ISSN] 1364-6915
  • [Journal-full-title] Aging & mental health
  • [ISO-abbreviation] Aging Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Dementia / nursing home / psychotropics
  •  go-up   go-down


10. Sauer J, Tabet N, Howard R: Alpha lipoic acid for dementia. Cochrane Database Syst Rev; 2004;(1):CD004244
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha lipoic acid for dementia.
  • BACKGROUND: Oxidative processes have been implicated in the pathogenesis of neurodegenerative dementias including Alzheimer's disease.
  • These properties might qualify ALA for a modulatory role in the treatment of people with dementia.
  • OBJECTIVES: To assess the role and clinical efficacy of alpha lipoic acid in the treatment of dementia.
  • SEARCH STRATEGY: A search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) on 3 February 2003 using the terms 'alpha lipoic acid' and 'thioctic'.
  • SELECTION CRITERIA: All double-blind randomized placebo-controlled trials examining the efficacy of alpha lipoic acid in dementia DATA COLLECTION AND ANALYSIS: No trials were found that met the selection criteria MAIN RESULTS: No meta-analysis could be performed.
  • A systematic search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, as well as registers of ongoing and unpublished trials could not identify any studies investigating the use of ALA for dementia.
  • REVIEWER'S CONCLUSIONS: In the absence of randomized double-blind placebo-controlled trials investigating ALA for dementia, no evidence exists to explore any potential effects.
  • Until data from trials become available for analysis, ALA cannot be recommended for people with dementia.
  • [MeSH-major] Dementia / drug therapy. Thioctic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14974062.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 73Y7P0K73Y / Thioctic Acid
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement